Tango Therapeutics, Inc. (TNGX) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 10 Buy.
The consensus price target is $15.60 (low: $12.00, high: $19.00), representing a downside of 38.4% from the current price $25.33.
Analysts estimate Earnings Per Share (EPS) of $-1.20 and revenue of $0.05B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.19 vs est $-1.20 (beat +0.9%). 2025: actual $-0.87 vs est $-0.87 (beat +0.2%). Analyst accuracy: 99%.
TNGX Stock — 12-Month Price Forecast
$15.60
▼ -38.41% Downside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for Tango Therapeutics, Inc., the average price target is $15.60, with a high forecast of $19.00, and a low forecast of $12.00.
The average price target represents a -38.41% change from the last price of $25.33.
Highest Price Target
$19.00
Average Price Target
$15.60
Lowest Price Target
$12.00
TNGX Analyst Ratings
Buy
Based on 10 analysts giving stock ratings to Tango Therapeutics, Inc. in the past 3 months
EPS Estimates — TNGX
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.19
vs Est –$1.20
▲ 0.9% off
2025
Actual –$0.87
vs Est –$0.87
▲ 0.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — TNGX
95%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.042B
vs Est $0.046B
▼ 9.4% off
2025
Actual $0.062B
vs Est $0.063B
▼ 0.7% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
